# NEURONETICS, INC. (STIM) · Edgar & Edgarette company card

> Neuronetics (STIM) grew revenue 99.2% in FY2025 to $149 million, operating margin -21.1% against a 1.2% median for surgical & medical instruments & apparatus, equity 15.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1227636 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/STIM) · [JSON](https://www.pops4.com/boards/company/STIM.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $149M |
| Revenue growth, 1 year | 99.2% |
| Revenue growth per year | 28.1% |
| Operating margin | -21.1% (prior year -46.2%) |
| Net margin | -26.2% |
| Operating cash flow | −$20M |
| Capital spending | $801,000 |
| Free cash flow | −$21M |
| Cash | $28M |
| Long-term debt | $66M |
| Total assets | $142M |
| Total equity | $22M |
| Equity ÷ assets | 15.8% |
| Return on equity | -174.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -10.42 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.58 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative; operating loss: a margin of -21.1% in FY2025; revenue is hard to predict: its 80% range is ±35%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $149.2M (FY2025), total debt $65.8M. Experience: revenue up 99.2% on the year, up 28.1% a year over 4 years; operating margin -21.1%, up from -46.2%. Soundness: equity 15.8% of assets, return on equity -174.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $168.7M and $349.9M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $140.2M to $424.0M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -21.1% against a 1.2% median; growth 99.2% against 11.6%.

Range logged 2026-11-01, receipt 5846710af62f8b6c, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-04-06 ([filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526143876/0001193125-26-143876-index.htm))
- Item 5.02 Director or officer change: 8, latest 2026-08-17 ([filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526354051/0001193125-26-354051-index.htm))

## Recent filings

- 8-K · filed 2026-11-10 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526455457/0001193125-26-455457-index.htm)
- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1227636/000110465926122380/0001104659-26-122380-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526446239/0001193125-26-446239-index.htm)
- 8-K · filed 2026-08-17 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526354051/0001193125-26-354051-index.htm)
- 10-Q · filed 2026-08-11 · [filing](https://www.sec.gov/Archives/edgar/data/1227636/000110465926094078/0001104659-26-094078-index.htm)
- 8-K · filed 2026-08-11 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1227636/000119312526343474/0001193125-26-343474-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001227636.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1227636

## Cite

POPS4, Edgar & Edgarette: NEURONETICS, INC. (STIM) company card, from the company's own SEC filings, accessed 2026-11-11, https://www.pops4.com/boards/company/STIM. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.